

Biomed Research International

Symphysis-fundal height curve in pregnancies complicated by maternal hyperglycemia

– comparison with curves of non-diabetic pregnant women (#1908764)

Supplementary materials

Table 1A. Glycemic control assessed between 13 and 39 weeks among pregnant women with T2DM, GDM and MGH

Weeks	# glucose tests	minimum	maximum	mean (mg/dL)
13	27	87.60	233.30	123.12
14	33	72.40	213.00	120.65
15	25	70.40	189.60	118.60
16	35	87.90	186.00	117.11
17	31	69.60	249.10	110.71
18	33	67.30	170.30	109.62
19	37	66.30	161.90	112.84
20	40	69.70	216.80	116.52G
21	42	73.20	240.00	111.31
22	46	80.00	170.80	115.08
23	46	72.20	273.50	123.94
24	69	76.20	174.00	111.01
25	76	76.30	180.80	112.06
26	88	79.70	188.50	110.37
27	83	75.10	334.70	113.62
28	116	56.40	235.50	111.93
29	89	79.20	157.30	108.89
30	110	54.00	281.80	109.35
31	109	72.00	198.00	109.56
32	139	61.80	198.20	109.01
33	145	76.80	236.30	106.53
34	149	52.80	152.50	104.14
35	167	67.40	180.90	100.91
36	163	58.80	187.50	99.31
37	124	64.10	138.00	98.38
38	41	77.50	124.00	100.16
39	11	81.10	106.30	94.46

Table 2A. SFH expected value with upper and lower limits (95% CI) between 13 and 42 weeks or gestation among pregnant women with T2DM, GDM and MGH

SFH = 1.082 + 0.966*semana			
SFH (LL) = 0.629 + 0.95*week			
SFH (UL) = 1.535 + 0.981*week			
95%CI*			
Week	Expected SFH	LL	UL
13	13.64	12.98	14.29
14	14.61	13.93	15.27
15	15.57	14.88	16.25
16	16.54	15.83	17.23
17	17.50	16.78	18.21
18	18.47	17.73	19.19
19	19.44	18.68	20.17
20	20.40	19.63	21.16
21	21.37	20.58	22.14
22	22.33	21.53	23.12
23	23.30	22.48	24.10
24	24.27	23.43	25.08
25	25.23	24.38	26.06
26	26.20	25.33	27.04
27	27.16	26.28	28.02
28	28.13	27.23	29.00
29	29.10	28.18	29.98
30	30.06	29.13	30.97
31	31.03	30.08	31.95
32	31.99	31.03	32.93
33	32.96	31.98	33.91
34	33.93	32.93	34.89
35	34.89	33.88	35.87
36	35.86	34.83	36.85
37	36.82	35.78	37.83
38	37.79	36.73	38.81
39	38.76	37.68	39.79
40	39.72	38.63	40.78
41	40.69	39.58	41.76
42	41.65	40.53	42.74

*LL = lower limit

UL = upper limit